US Patent 7,199,098: Glatiramer Acetate Claim Scope, Expiration, Orange Book Status and Patent Landscape

US Patent 7,199,098 protected a defined molecular-weight profile of copolymer-1, the active polypeptide mixture marketed as glatiramer acetate under Copaxone. The patent covered compositions concentrated in the 2–20 kDa range, with limited high-molecular-weight material, manufacturing conditions using a 1:5:2:4 monomer ratio, and compositions asserted to have lower toxicity than higher-molecular-weight copolymer-1.

The patent was granted on April 3, 2007, and its standard 20-year term ran from the underlying nonprovisional filing date, resulting in expiration on December 20, 2022. It no longer blocks generic glatiramer acetate entry. Its commercial significance was greatest before and during the first wave of abbreviated new drug application, or ANDA, litigation involving Copaxone.

What drug does US Patent 7,199,098 protect?

US Patent 7,199,098 protects a particular form of copolymer-1, also called glatiramer or glatiramer acetate. Copolymer-1 is a heterogeneous synthetic mixture of polypeptides containing four amino-acid residues:

Glutamic acid
Lysine
Alanine
Tyrosine

The patent does not claim a single defined peptide sequence. It claims a non-uniform mixture in which individual polymer chains differ in both molecular weight and amino-acid sequence.

Copolymer-1 is the active ingredient in Teva’s Copaxone products for relapsing forms of multiple sclerosis. The FDA approved Copaxone 20 mg/mL in 1996 and later approved a 40 mg/mL three-times-weekly regimen.[2]

The patent’s technical focus is molecular-weight control. It sought to distinguish lower-molecular-weight copolymer-1 from material containing a greater proportion of high-molecular-weight chains, which the patent associated with increased toxicity.

What are the independent claims of US Patent 7,199,098?

The patent has three principal independent claim groups: composition claims, process claims, and product-by-process composition claims.

Claim group	Independent claims	Core limitation
Composition	1	Non-uniform copolymer-1 mixture; more than 75% of polymers between 2 and 20 kDa; less than 5% above 40 kDa; suitable for treating multiple sclerosis
Process	15	Polymerization using specified protected amino-acid starting materials in a 1:5:2:4 molar ratio, followed by deprotection and isolation
Product-by-process	17	Copolymer-1 composition averaging about 4 to 8.6 kDa, preparable by the specified process
Functional composition	19	Copolymer-1 averaging about 4 to 8.6 kDa and exhibiting lower toxicity than material averaging above about 8.6 kDa

Claim 1 is the central composition claim. Claims 2 through 14 narrow claim 1 by specifying average molecular-weight ranges or the molecular-weight distribution shown in Figure 1.

Claim 15 is directed to the manufacturing process. Claims 16 and 18 narrow the process and product-by-process claims to specified average molecular-weight ranges.

Claim 19 uses a functional limitation: the claimed composition must exhibit lower toxicity than a copolymer-1 composition with an average molecular weight above approximately 8.6 kDa.

How broad is claim 1?

Claim 1 is broad in chemical identity but narrow in distributional characteristics.

It requires all of the following:

A mixture of copolymers containing alanine, glutamic acid, lysine and tyrosine.
A non-uniform mixture with respect to molecular weight and sequence.
More than 75% of the copolymer species, measured on a molar fraction basis, within 2 to 20 kDa.
Less than 5% of the copolymer species above 40 kDa.
Suitability for treating multiple sclerosis.

The claim does not require:

A particular amino-acid sequence.
A single molecular-weight species.
A specific injection dose.
A particular excipient.
A particular device or syringe.
A particular salt form stated expressly in the claim.
A specific manufacturing process.
A specific percentage composition of the four amino acids beyond the recited copolymer identity.

The “molar fraction basis” limitation is important. The claim measures the percentage of polymer molecules in the distribution, not the percentage of total polymer mass. A small number of very large molecules could contribute substantial mass without necessarily violating the molar-fraction limitation.

The phrase “suitable for treating multiple sclerosis” is also material. It ties the claimed composition to therapeutic utility, but it does not establish a dosing regimen or clinical efficacy threshold. In an infringement dispute, the practical question would be whether the accused product has the claimed molecular-weight profile and is approved, labeled, or otherwise made for multiple-sclerosis treatment.

What molecular-weight ranges are protected?

The dependent claims create overlapping molecular-weight windows rather than separate commercial products.

Claims	Average molecular-weight limitation
2 and 9	7,000 Da ± 2,000 Da, equivalent to approximately 5 to 9 kDa
3 and 10	4 to 8.6 kDa
4 and 11	6.25 to 8.4 kDa
5 and 12	4 to 8 kDa
6 and 13	7 to 8 kDa
7 and 14	Distribution depicted in Figure 1 for a 7.7 kDa average
8 through 14	Less than 2.5% above 40 kDa, combined with the applicable average range

Claims 8 through 14 impose a tighter high-molecular-weight ceiling than claim 1. Claim 1 permits less than 5% above 40 kDa. Claim 8 requires less than 2.5% above 40 kDa.

The claims contain overlapping ranges. For example, a product averaging 7.5 kDa could fall within the ranges of claims 2, 4, 5, and 6 if it also satisfies the applicable high-molecular-weight limitations.

The distribution limitation is likely more important than the average alone. Two mixtures can have the same average molecular weight but materially different tails, including different proportions above 20 kDa or 40 kDa.

What manufacturing process does claim 15 protect?

Claim 15 requires a defined polymerization and deprotection sequence:

Process element	Claimed requirement
Tyrosine component	N-carboxyanhydride of tyrosine
Alanine component	N-carboxyanhydride of alanine
Glutamate component	Gamma-benzyl glutamate
Lysine component	Trifluoroacetyllysine
Starting-material ratio	1:5:2:4
First stage	Formation of protected polypeptides
Second stage	Deprotection
Final stage	Isolation of unprotected copolymer-1
Resulting average	4 to about 9 kDa in claim 15; narrower ranges in claim 16

The exact identity of the protected starting materials and their ratio narrows the process claim. A manufacturer could potentially avoid literal infringement by using a different protected amino-acid derivative, a materially different molar ratio, or a different synthesis route, provided the alternative process does not fall within an equivalent scope under applicable infringement principles.

The process claims do not cover every method of making glatiramer acetate. They target the specified route and the resulting average molecular-weight profile.

How do the product-by-process claims operate?

Claim 17 covers a copolymer-1 composition “preparable by” the process recited in claim 15. Claim 18 narrows the composition to an average molecular weight of 6.25 to 8.4 kDa.

Product-by-process claims are generally assessed by the identity and characteristics of the product, although the claimed process can affect the scope and evidentiary analysis. For an ANDA applicant, the relevant risk would not be limited to whether the manufacturing process is identical on paper. The resulting composition, analytical profile, and any legally relevant process limitation would all matter.

A generic manufacturer using a different synthesis route could still face risk if its product meets the substantive product limitations and the claim is interpreted to cover the resulting composition. Conversely, a process that uses the claimed starting materials and ratio but produces a materially different molecular-weight distribution could raise a separate scope issue.

What does the lower-toxicity limitation in claim 19 require?

Claim 19 requires a composition that:

Contains glutamic acid, lysine, alanine and tyrosine residues.
Has an average molecular weight of about 4 to about 8.6 kDa.
Is non-uniform in molecular weight and sequence.
Exhibits lower toxicity than a composition averaging more than about 8.6 kDa.

This is a comparative limitation. It requires a reference point: a higher-average-molecular-weight copolymer-1 composition.

The patent does not state in the claim a single mandatory toxicity assay, dose, animal model, or statistical threshold. That creates an enforcement issue. In litigation, the patent owner would need to establish how “lower toxicity” is measured and what comparison material qualifies as the greater-than-8.6-kDa comparator.

Claim 20 narrows claim 19 to an average molecular weight of 6.25 to 8.4 kDa.

When did US Patent 7,199,098 expire?

US Patent 7,199,098 expired on December 20, 2022, based on the 20-year term from the underlying US nonprovisional filing date. The patent was granted on April 3, 2007.[1]

Event	Date
Earliest priority date identified in the patent record	December 20, 2001
US nonprovisional filing date used for patent term	December 20, 2002
Patent grant	April 3, 2007
Standard patent-term expiration	December 20, 2022
Current status	Expired

The patent’s expiration means that claims 1 through 20 no longer provide an enforceable exclusionary right in the United States. The expiration does not erase historical infringement exposure for conduct occurring before expiration, subject to applicable defenses, damages limits, and litigation-specific issues.

What was the Orange Book status of US Patent 7,199,098?

The patent was part of the US patent landscape surrounding Copaxone and generic glatiramer acetate. Orange Book relevance must be separated from enforceability.

An Orange Book listing identifies patents submitted for an approved drug product. It does not extend the patent term and does not establish that every claim is valid or infringed. After expiration, the listing has no continuing ability to block approval based on the patent’s term.

The principal FDA regulatory framework was:

NDA 020622 for Copaxone.
20 mg/mL daily administration.
40 mg/mL three-times-weekly administration.
ANDA approvals for generic glatiramer acetate products.

Because glatiramer acetate is a synthetic heterogeneous mixture rather than a conventional single-molecule small chemical, FDA approval required product-specific analytical and immunological comparability work. It is regulated through the ANDA framework, not the biosimilar pathway.

Which companies challenged Copaxone patent protection?

The principal commercial challengers included Sandoz, Mylan and other generic-drug applicants. Generic competition reached the market in stages:

Company or product	General market significance
Sandoz Glatopa	Early FDA-approved generic glatiramer acetate, including 20 mg/mL
Mylan glatiramer acetate	Generic competition in 20 mg/mL and later 40 mg/mL presentations
Other ANDA applicants	Expanded competition after core Copaxone patents and later regimen patents faced expiration or successful challenges

The most consequential Copaxone litigation often involved patents other than US 7,199,098, particularly patents directed to dosing frequency and the 40 mg/mL three-times-weekly regimen. Teva’s later patent disputes included US Patent Nos. 8,232,250 and 8,399,413, which were litigated in the Federal Circuit in connection with generic glatiramer acetate products.[3]

The legal risk associated with US 7,199,098 declined sharply after December 2022 because the patent expired. Earlier ANDA disputes could still have involved the patent, but current generic launch analysis must focus on later-expiring patents, FDA exclusivity, product-specific regulatory requirements, and commercial execution.

How does US 7,199,098 compare with other Copaxone patents?

Patent category	Protection focus	Commercial relevance
Early copolymer-1 patents	Basic composition and therapeutic use	Historically important; generally expired
US 7,199,098	Molecular-weight distribution, low average molecular weight, toxicity profile and process	Relevant to composition and manufacturing challenges before 2022
Dosing patents	40 mg/mL three-times-weekly administration	More relevant to later Copaxone 40 mg litigation
Device and formulation patents	Syringe, excipient, stability or delivery attributes	Potentially product-specific and narrower
Regulatory exclusivity	FDA approval and labeling protection	Separate from patent rights

US 7,199,098 is not a broad monopoly on all glatiramer acetate. Its scope is tied to the distribution and average molecular weight of the heterogeneous polypeptide mixture. A competing product with the same four amino-acid components but a materially different profile could present a different infringement analysis.

How strong was the patent estate?

The estate was technically meaningful but legally narrow compared with a basic composition patent.

Strengths

It targeted the commercial product’s heterogeneous molecular-weight profile.
It covered both composition and manufacturing concepts.
It included overlapping average molecular-weight ranges.
It addressed high-molecular-weight tail control, which can be difficult to avoid while maintaining product comparability.
It created analytical obligations for potential generic manufacturers.

Limitations

It did not claim every glatiramer composition.
Average molecular weight alone did not establish infringement.
Molecular-weight testing methodology could affect claim interpretation and reproducibility.
Claim 19 relied on a comparative toxicity limitation without specifying a single test protocol.
The patent expired in 2022.
Generic applicants could challenge validity, claim construction, or infringement while developing alternative processes.

The patent was strongest as a product-characterization and manufacturing barrier during its enforceable term. It was weaker as a long-term platform patent because it did not control all four-amino-acid copolymer mixtures or all MS uses.

What generic launch risks existed?

Before expiration, generic applicants faced four principal risks:

Product profile risk. The applicant’s molecular-weight distribution could fall inside the claimed ranges.
Process risk. The synthesis route could use the claimed protected monomers and 1:5:2:4 ratio.
Analytical risk. Different testing methods could produce conflicting average molecular-weight or tail measurements.
Litigation timing risk. A Paragraph IV certification could trigger patent litigation and a 30-month stay under the Hatch-Waxman framework.

After December 20, 2022, the patent-specific launch risk ended in the United States. Remaining risks shifted to:

Later-expiring Copaxone regimen patents.
FDA review of complex mixture comparability.
Manufacturing scale-up.
Device and presentation differences.
Labeling and substitution rules.
Commercial pricing and payer contracting.

What biosimilar risk applies to glatiramer acetate?

Glatiramer acetate does not present conventional biosimilar risk because it is not an originator biologic approved under the biologics license application pathway. Generic manufacturers generally pursue ANDAs rather than abbreviated biologics license applications.

The practical regulatory difficulty is still significant. Glatiramer acetate is a complex, heterogeneous mixture. FDA review can require extensive structural, physicochemical, compositional and immunological characterization, even though the legal pathway is an ANDA.

The absence of biosimilar status does not eliminate technical barriers. It changes the statutory approval mechanism and substitution framework.

What licensing and commercial rights shaped the market?

Teva commercialized glatiramer acetate based on rights associated with the Weizmann Institute and related research entities. The commercial patent record identifies Teva-related ownership and prosecution interests for the Copaxone patent estate.[1]

The commercial value of US 7,199,098 was linked to Copaxone revenue during the period when Teva held substantial market share in multiple sclerosis. The patent helped protect a specific product-quality profile rather than the entire therapeutic class.

Public company filings reported Copaxone as a major Teva revenue product before generic erosion. The precise revenue exposure varied by year, dose strength and geography. US erosion accelerated after generic approvals for 20 mg/mL and 40 mg/mL products. Once US 7,199,098 expired, its direct contribution to exclusivity value became zero, although Teva’s broader patent, regulatory and commercial defenses continued to affect market share.[4]

What is the current competitive landscape?

The US glatiramer acetate market includes:

Teva Copaxone.
Sandoz Glatopa.
Mylan/Viatris generic glatiramer acetate.
Other ANDA-approved or potential generic products.

Competition is based on:

20 mg/mL daily versus 40 mg/mL three-times-weekly dosing.
Injection-device convenience.
Substitution status.
Payer access.
Net price.
Patient-support programs.
Supply reliability.

The expiration of US 7,199,098 removed a molecular-weight composition barrier, but it did not by itself determine all market-entry outcomes. A complete launch analysis must evaluate every unexpired patent listed for the relevant Copaxone strength and dosing regimen.

Key Takeaways

US Patent 7,199,098 covered low-average-molecular-weight copolymer-1 mixtures used for glatiramer acetate.
Claim 1 requires more than 75% of polymer species between 2 and 20 kDa and less than 5% above 40 kDa.
Claims 8 through 14 impose a stricter less-than-2.5% high-molecular-weight limit.
Claims 15 through 18 target a specific manufacturing route using a 1:5:2:4 starting-material ratio.
Claims 19 and 20 add a comparative lower-toxicity limitation.
The patent expired on December 20, 2022.
It is no longer a current US barrier to generic glatiramer acetate entry.
It was not a patent on every glatiramer acetate composition.
Current competition is governed by later-expiring regimen, formulation, device and regulatory issues rather than this patent.
Glatiramer acetate is approved through the ANDA pathway, not the biosimilar pathway.

FAQs

Is US Patent 7,199,098 still enforceable against generic glatiramer acetate?

No. The patent expired on December 20, 2022, so it no longer provides an enforceable US exclusionary right for future conduct.

Does US 7,199,098 cover Copaxone 40 mg three-times-weekly dosing?

Not specifically. The patent focuses on composition, molecular-weight distribution and manufacturing. Separate patents addressed the 40 mg/mL three-times-weekly regimen.

Can a glatiramer acetate product avoid the patent by using a different amino-acid sequence?

The claimed mixture is inherently non-uniform in sequence, so sequence diversity is part of the claim. A product would need to be assessed against all chemical, distributional and therapeutic limitations, not sequence uniformity alone.

Does the patent require the acetate salt?

The claims provided identify copolymer-1 and the four amino-acid residues. They do not expressly recite “acetate” in every claim. Salt and product identity would require claim-construction and product-specific analysis.

Is glatiramer acetate a biologic for FDA purposes?

No. FDA-approved glatiramer acetate products use the ANDA framework applicable to generic drug products, although the active ingredient’s heterogeneous structure creates complex analytical and manufacturing requirements.

References

United States Patent and Trademark Office. (2007). U.S. Patent No. 7,199,098, Copolymer-1 compositions and methods of use thereof.
U.S. Food and Drug Administration. (1996). Copaxone (glatiramer acetate) prescribing information and approval history.
Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 876 F.3d 1359 (Fed. Cir. 2017).
Teva Pharmaceutical Industries Ltd. (2022). Annual report and Form 20-F.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0762888	⤷ Start Trial	90987	Luxembourg	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300096	Netherlands	⤷ Start Trial
European Patent Office	0762888	⤷ Start Trial	C300251	Netherlands	⤷ Start Trial
Austria	212857	⤷ Start Trial
Australia	1016102	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,199,098

Summary for Patent: 7,199,098